This section compiles and harmonizes information on pharmacological agents
that activate, inhibit, or otherwise modulate the NRF2 signaling pathway. The
accompanying Excel datasets
consolidate evidence from preclinical and clinical studies, highlighting both novel compounds and repurposed drugs with demonstrated activity on NRF2 and associated oxidative stress and inflammation pathways. The resource
categorizes compounds according to their mechanism of action, molecular targets, pharmacodynamic profiles, and therapeutic indications.
The deliverable is aligned with our publications emphasizing NRF2 as a key therapeutic axis in noncommunicable diseases, including studies such as
“NRF2 in chronic diseases: Mechanisms, targets, and new therapeutic opportunities”
(Free Radic. Biol. Med., 2022),
https://www.sciencedirect.com/science/article/abs/pii/S0891584922011340?via
%3Dihub
“NRF2 modulation as a strategy for neuroprotection in Parkinson’s disease”
(PubMed ID: 36086898)
https://pubmed.ncbi.nlm.nih.gov/36086898/
“NRF2-directed therapies: From chemical biology to clinical translation”
(PubMed ID: 40059038).
https://pubmed.ncbi.nlm.nih.gov/40059038/
Together, these datasets and associated publications provide a robust technological foundation for evidence-based drug discovery and repurposing within the BenBedPhar network, strengthening the Action’s translational mission
from molecular mechanisms to clinical applications.
